Adam K. Stern

October 7, 2026

DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction. DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.

October 6, 2026

MTNB Listed Among 12 Health Care Stocks Moving After-Market. Matinas Biopharma was included in a Benzinga list of 12 health care stocks that saw movement in Monday's after-market session. This indicates the stock experienced notable trading activity outside regular hours, likely due to recent developments or market sentiment. The company's stock has a wide 52-week range, reflecting its volatile nature.

October 7, 2026

Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing. Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.